Allena Pharmaceuticals, Inc. Total Assets

Total Assets of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Total Assets growth rates and interactive chart. Total assets are the sum of all current and noncurrent assets and must equal the sum of total liabilities and stockholders' equity combined. In the accounting industry, assets are defined as anything that a business owns, has value, and can be converted to cash.

Highlights and Quick Summary

  • Total Assets for the quarter ending March 31, 2022 was $21.7 Million (a -37.47% decrease compared to previous quarter)
  • Year-over-year quarterly Total Assets decreased by -28.24%
  • Annual Total Assets for 2021 was $34.8 Million (a -10.72% decrease from previous year)
  • Annual Total Assets for 2020 was $38.9 Million (a 14.14% increase from previous year)
  • Annual Total Assets for 2019 was $34.1 Million (a -47.71% decrease from previous year)
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Total Assets of Allena Pharmaceuticals, Inc.

Most recent Total Assetsof ALNA including historical data for past 10 years.

Interactive Chart of Total Assets of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Total Assets for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $21.73 – – – –
2021 $34.76 $43.87 $30.29 $40.47 $34.76
2020 $38.93 $31.97 $29.11 $23.67 $38.93
2019 $34.11 $42.77 $53.58 $54.81 $34.11
2018 $65.23 $73.4 $80.06 $87.57 $65.23
2017 $96.25 $36.26 $0.0 $0.0 $96.25
2016 – – $0.0 $0.0 $49.48
2015 $70.0 – – – $70.01

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
© stockrow.com